Stockscreener 앱 받기
13.56
0.37%
0.05
시간 외 거래:
13.30
-0.26
-1.92%
전일 마감가:
$13.51
열려 있는:
$13.11
하루 거래량:
1.49M
Relative Volume:
1.88
시가총액:
$883.78M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-4.967
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
+0.74%
1개월 성능:
-6.42%
6개월 성능:
+32.94%
1년 성능:
+14.62%
1일 변동 폭
$12.59
$13.94
1주일 범위
$12.59
$13.94
52주 변동 폭
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.56 | 880.52M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond - TipRanks
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $26 to $45 - 富途牛牛
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position - TipRanks
Mineralys signals pre-NDA meeting for lorundrostat in Q4 2025 while expanding clinical programs into cardiorenal comorbidities - MSN
Mineralys Therapeutics Q2 2025: Unraveling Contradictions in Manufacturing, Trials, and Market Strategies - AInvest
Mineralys Therapeutics Reports Positive Q2 2025 Results - TipRanks
Transcript : Mineralys Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Mineralys Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Mineralys Therapeutics beats Q2 2025 EPS forecast, stock rises - Investing.com Nigeria
Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView
Mineralys Therapeutics Q2 GAAP Loss Narrows - MarketScreener
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Mineralys' Hypertension Drug Shows Promise in Multiple Studies, Heads Toward FDA Filing - Stock Titan
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding - simplywall.st
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 - The Manila Times
Momentum Screeners Rank Mineralys Therapeutics Inc. in Top 5 TodaySwing Trading Plan With Smart Signals in Review - beatles.ru
Support Zone Holds Steady for Mineralys Therapeutics Inc. After DipLow Capital High Return Stock Plans Reviewed - metal.it
Mineralys Therapeutics to Announce Second Quarter 2025 - GlobeNewswire
What drives Mineralys Therapeutics Inc. stock priceAchieve consistent profits with smart trading - Jammu Links News
How many analysts rate Mineralys Therapeutics Inc. as a “Buy”Explosive trading growth - Jammu Links News
What are Mineralys Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for risk management - Jammu Links News
What catalysts could drive Mineralys Therapeutics Inc. stock higher in 2025Unlock exclusive trading tools and resources - Jammu Links News
Mineralys Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough investment performance - Jammu Links News
Is Mineralys Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart stock selection - Jammu Links News
What is the dividend policy of Mineralys Therapeutics Inc. stockCapitalize on market trends with confidence - jammulinksnews.com
How volatile is Mineralys Therapeutics Inc. stock compared to the marketMaster the art of timing market moves - Jammu Links News
How strong is Mineralys Therapeutics Inc. company’s balance sheetCapitalize on fast-moving trading opportunities - Jammu Links News
Is it the right time to buy Mineralys Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
CFO & Secretary Of Mineralys Therapeutics Sold 36% Of Their Shares - 富途牛牛
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034) | DelveInsight - Yahoo Finance
Mineralys Therapeutics Insider Sold Shares Worth $1,077,477, According to a Recent SEC Filing - 富途牛牛
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares - Investing.com
Mineralys CFO Sells 12946 Shares at $14.04/Share on 2025-07-28 - AInvest
What analysts say about Mineralys Therapeutics Inc. stock outlookRisk Adjusted Technical Entry Plan Gains Followers - beatles.ru
Why Mineralys Therapeutics Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - beatles.ru
Will Mineralys Therapeutics Inc. stock split in the near futureTrend Analysis for Safer Trades Gains Popularity - metal.it
Aldosterone Synthase Inhibitors Market is evolving rapidly - openPR.com
Intrinsic Value of Mineralys Therapeutics Inc. Stock: Is It Undervalued or OvervaluedAccurate Technical Trend Reversal Picks Detected - metal.it
Is Mineralys Therapeutics Inc. a growth stock or a value stockExceptional market positioning - Jammu Links News
Why is Mineralys Therapeutics Inc. stock attracting strong analyst attentionOutstanding trading profits - Jammu Links News
What are the latest earnings results for Mineralys Therapeutics Inc.Get real-time updates on market trends - Jammu Links News
What are the technical indicators suggesting about Mineralys Therapeutics Inc.Unrivaled growth potential - Jammu Links News
What is Mineralys Therapeutics Inc. company’s growth strategyPowerful market insights - jammulinksnews.com
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.67%
자본화:
|
볼륨(24시간):